跳至主要内容
临床试验/NCT01370096
NCT01370096终止2 期

Vasopressin and Inhaled Prostacyclin in Pediatric Pulmonary Hypertension

University of Alberta2 个研究点 分布在 1 个国家目标入组 3 人开始时间: 2012年2月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
终止
入组人数
3
试验地点
2
主要终点
PVR/SVR indexed ratio

研究概览

简要总结

To diagnose pulmonary hypertension, children have a cardiac catheterization to check the blood pressure in their lungs. Children with pulmonary hypertension have high blood pressure in their lungs. The right ventricle of the heart has to do more work to pump against this higher pressure. The investigators do not know the best medicine(s) to help children with pulmonary hypertension when their right ventricles fail. The purpose of the study is to look at the effects of two different medicines on the blood pressure in the lungs of a child with pulmonary hypertension. The investigators hope to then be able to choose the best medicine for children with pulmonary hypertension and right ventricular failure.

The first medicine is called vasopressin. It is a hormone that your body makes on its own. The investigators will be giving it through an intravenous infusion. The investigators think that vasopressin works differently in different parts of your body. The investigators are looking to see the different effects that vasopressin has in the lungs compared to the rest of the body.

The second medicine is called prostacyclin and is something that your body also makes by itself. Prostacyclin, given via an intravenous infusion, is a treatment for pulmonary hypertension as it decreases pressure in the blood vessels. In the catheterization laboratory, patients breathe in this medicine to measure specific changes in the blood pressure in their lungs.

详细描述

Background:

Pulmonary hypertension (PH) is a rare, but devastating disease that affects both adult and pediatric patients. Mortality is high with 84% survival at one year and 50% survival at five years in adult populations despite treatment. The cause of death is typically either from right ventricular failure or sudden cardiac death, likely secondary to a pulmonary hypertensive crisis. The resuscitation of patients with PH after cardiac arrest is extremely difficult. The use of epinephrine, a pulmonary vasoconstrictor, during resuscitation may impair filling of the left ventricle. The ideal resuscitation drug(s) would dilate the pulmonary vascular bed to help fill the left ventricle while constricting the systemic vascular bed to maintain coronary perfusion.

Objectives:

The assessment of pulmonary vascular reactivity is critical to the clinical management of patients with pulmonary hypertension (PH). The goals of this pilot study include determination of the hemodynamic effects of low dose vasopressin infusion and the effects of a combination of low dose vasopressin infusion and inhaled prostacyclin in a population of pediatric patients with PH.

Methods:

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
— 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • All pediatric patients with pulmonary hypertension defined as a mean pulmonary artery pressure ≥ 25mmHg undergoing diagnostic cardiac catheterization for clinical purposes are potential subjects. Subjects must have preserved left ventricular function (ejection fraction ≥ 40 %). Subjects must have parental consent for enrollment.

排除标准

  • Any patient with left ventricular dysfunction (EF < 40%).
  • Any patient with known pulmonary veno-occlusive disease

结局指标

主要结局

PVR/SVR indexed ratio

时间窗: Within 15 minutes of intervention

Cardiac cath data

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Lindsay Ryerson

Assistant professor

University of Alberta

研究点 (2)

Loading locations...

相似试验